0
0
May 31, 2025
Dengue fever, a mosquito-borne disease caused by the dengue virus (DENV), continues to pose a significant threat to global health, with nearly half of the world’s population at risk. Despite over a century of scientific effort, the development of a safe and effective dengue vaccine remains a complex challenge due to the virus’s unique biology and the risk of severe disease following vaccination.
A recent review published in Pediatric Investigation by Professor Kevin C. Kain (University of Toronto, Canada) and Dr. Ran Wang (Capital Medical University, China) sheds light on the current landscape of dengue vaccine development, the hurdles faced, and the future directions for research.
The Four Faces of Dengue
DENV exists as four distinct serotypes (DENV-1 to DENV-4), each capable of causing infection. A primary infection typically results in serotype-specific immunity, but subsequent infections with a different serotype can trigger a more severe form of the disease due to a phenomenon known as antibody-dependent enhancement (ADE). ADE occurs when antibodies from a previous infection facilitate viral entry into immune cells, exacerbating the disease rather than protecting against it.
The Vaccine Landscape: Progress and Pitfalls
The review highlights three major vaccines:
-
CYD-TDV (Dengvaxia): The first licensed dengue vaccine, CYD-TDV, showed efficacy in clinical trials but was less effective against certain serotypes and posed safety concerns for those without prior dengue exposure. Its three-dose, year-long regimen also limited its practicality in resource-constrained settings, leading to its withdrawal from widespread use. The World Health Organization (WHO) now recommends it only for individuals aged 9-45 years with confirmed prior dengue infection.
-
TAK-003: This vaccine underwent extensive phase III trials across eight dengue-endemic countries, demonstrating an overall efficacy of 61.2% against dengue and 84.1% against hospitalization. It provided strong protection against DENV-1 and DENV-2, but data on DENV-3 and DENV-4 remain insufficient. The two-dose regimen still presents logistical challenges.
-
Butantan-DV: Offering a single-dose solution, Butantan-DV has shown promising results, with an overall efficacy of 73.6% in dengue-naïve individuals and 89.2% in those with prior exposure. Notably, it significantly reduced severe dengue cases. However, its effectiveness against DENV-3 and DENV-4 is yet to be determined.
Ongoing Challenges
A central concern in dengue vaccine development is the risk of ADE, where vaccination could inadvertently increase the risk of severe disease upon subsequent infection. Understanding the mechanisms behind ADE, particularly the role of conserved viral epitopes and immune cell signaling, is crucial. The review emphasizes the need for ongoing phase IV (post-marketing) studies to monitor real-world vaccine performance and safety.
Additionally, the impact of current vaccines on older adults (over 60 years) remains unclear, highlighting the need for broader research.
The Road Ahead
Experts advocate for global collaboration among researchers, health agencies, and vaccine developers to accelerate progress. Future priorities include:
-
Conducting robust phase IV trials to refine vaccination strategies.
-
Developing vaccines effective across all age groups and serotypes.
-
Exploring innovative platforms, such as mRNA vaccines.
-
Designing region-specific vaccines to target local DENV variants.
With continued research, advanced technologies, and international cooperation, there is renewed hope that an effective, universally applicable dengue vaccine may soon become a reality—potentially transforming the fight against this persistent global health threat.
Disclaimer:
This article is based on a summary of findings published in a recent review in Pediatric Investigation and information from News-Medical.net. It is intended for informational purposes only and should not be considered as medical advice. For personal health concerns or questions about vaccines, please consult a qualified healthcare professional.
Citations:
